Alcohol intake and mortality among women with invasive breast cancer
British Journal of Cancer,  Clinical Article

H R Harris et al. –These findings suggest that alcohol intake up to approximately one small drink per day does not negatively impact breast cancer–specific survival and a half drink per day is associated with a decreased risk of mortality from other causes.

Methods

  • Investigated whether alcohol intake was associated with survival among 3146 women diagnosed with invasive breast cancer in the Swedish Mammography Cohort
  • Alcohol consumption was estimated using food frequency questionnaire
  • Cox proportional hazard models were used to calculate HRs and 95% CIs

Results

  • From 1987 to 2008 there were 385 breast cancer–specific deaths and 860 total deaths
  • No significant association was observed between alcohol intake and breast cancer–specific survival
  • Women who consumed 10?g per day (corresponding to approximately 0.75 to 1 drinks) or more of alcohol had an adjusted HR (95% CI) of breast cancer–specific death of 1.36 (0.82–2.26;ptrend=0.47) compared with non–drinkers
  • Significant inverse association was observed between alcohol and non–breast cancer deaths
  • Those who consumed 3.4–9.9?g per day of alcohol had a 33% lower risk of death compared with non–drinkers (95% CI 0.50–0.90;ptrend=0.04)

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the Randomized SweDCIS Trial Journal of Clinical Oncology, October 17, 2014    Clinical Article

2 Everolimus plus exemestane for hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Overall survival results from BOLERO-2 Annals of Oncology, September 30, 2014    Clinical Article

3 Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score Journal of Clinical Oncology, October 27, 2014    Clinical Article

4 Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: A real-world multicenter observational analysis. The RETROHER study Breast Cancer Research and Treatment, October 10, 2014    Clinical Article

5 Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial The Lancet Oncology, October 7, 2014    Clinical Article

6 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 23, 2014    Clinical Article

7 Mammographic density phenotypes and risk of breast cancer: A meta-analysis Journal of the National Cancer Institute, May 15, 2014

8 A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer Full Text The Oncologist, October 16, 2014    Free full text    Clinical Article

9 Tumor marker usage and medical care costs among older early-stage breast cancer survivors Journal of Clinical Oncology, October 24, 2014    Clinical Article

10 Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial The Lancet Oncology, October 15, 2014    Clinical Article

11 Risk determination and prevention of breast cancer Breast Cancer Research, October 6, 2014    Review Article

12 Breast cancer risk in young women in the National Breast Screening Programme: Implications for applying NICE guidelines for additional screening and chemoprevention Cancer Prevention Research, October 6, 2014    Clinical Article

13 Breast edema in breast cancer patients following breast-conserving surgery and radiotherapy: A systematic review Breast Cancer Research and Treatment, October 15, 2014    Review Article

14 Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study BMJ, October 22, 2014    Clinical Article

15 Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California Cancer Epidemiology, October 15, 2014    Clinical Article

16 Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: An observational cohort study Journal of Clinical Oncology, October 9, 2014    Clinical Article

17 Participants' understanding of a randomized controlled trial (RCT) through informed consent procedures in the RCT for breast cancer screening, J-START Full Text Trials, October 15, 2014    Free full text    Evidence Based Medicine    Clinical Article

18 Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial The Lancet Oncology, October 8, 2014    Clinical Article

19 Tumor-stroma crosstalk: Targeting stroma in breast cancer Current Opinion in Oncology, October 22, 2014    Clinical Article

20 Surgical treatment of breast cancer in patients aged 80 years or older – how much is enough? Full Text BMC Cancer, October 6, 2014    Free full text    Review Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore